Management of novel influenza epidemics in Singapore: Consensus recommendations from the Hospital Influenza Workgroup (Singapore). Ang, B., Archuleta, S., Chiew, Y. F., Chlebicki, M. P., Chua, A., Fisher, D. A., Hsu, L. Y., Kang, M. L., Koh, Y. L., Kurup, A., Lee, C. C., Leo, Y. S., Leong, H. N., Lim, P. L., Ling, L. M., Ling, M. L., Lye, D. C. B., Tambyah, P., Tan, T. T., & Wilder-Smith, A. Singapore Medical Journal, 50(6):567–580, 2009.
Management of novel influenza epidemics in Singapore: Consensus recommendations from the Hospital Influenza Workgroup (Singapore) [link]Paper  abstract   bibtex   
The recent emergence and global spread of a novel strain of influenza A (H1N1) virus has resulted in the first influenza pandemic of the 21st century. With its rapid spread to more than 70 countries within three months, governments are faced with the challenge of either containing or mitigating this influenza pandemic. The aim of this paper is to provide evidence-based consensus recommendations in the areas of infection control, antiviral treatment, chemoprophylaxis, antibiotic stockpiling and vaccination to guide decisionmaking for clinicians and administrators within the Singapore context. As the transmissibility and virulence of this new influenza A (H1N1) virus may evolve over time, we have tailored our recommendations according to several potential scenarios of viral virulence and transmissibility.
@article{ang_management_2009,
	title = {Management of novel influenza epidemics in {Singapore}: {Consensus} recommendations from the {Hospital} {Influenza} {Workgroup} ({Singapore})},
	volume = {50},
	issn = {0037-5675},
	url = {http://smj.sma.org.sg/5006/5006pp1.pdf http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=355017456},
	abstract = {The recent emergence and global spread of a novel strain of influenza A (H1N1) virus has resulted in the first influenza pandemic of the 21st century. With its rapid spread to more than 70 countries within three months, governments are faced with the challenge of either containing or mitigating this influenza pandemic. The aim of this paper is to provide evidence-based consensus recommendations in the areas of infection control, antiviral treatment, chemoprophylaxis, antibiotic stockpiling and vaccination to guide decisionmaking for clinicians and administrators within the Singapore context. As the transmissibility and virulence of this new influenza A (H1N1) virus may evolve over time, we have tailored our recommendations according to several potential scenarios of viral virulence and transmissibility.},
	language = {English},
	number = {6},
	journal = {Singapore Medical Journal},
	author = {Ang, B. and Archuleta, S. and Chiew, Y. F. and Chlebicki, M. P. and Chua, A. and Fisher, D. A. and Hsu, L. Y. and Kang, M. L. and Koh, Y. L. and Kurup, A. and Lee, C. C. and Leo, Y. S. and Leong, H. N. and Lim, P. L. and Ling, L. M. and Ling, M. L. and Lye, D. C. B. and Tambyah, P. and Tan, T. T. and Wilder-Smith, A.},
	year = {2009},
	keywords = {*Influenza virus A H1N1, *amantadine/do [Drug Dose], *amantadine/dt [Drug Therapy], *amantadine/pe [Pharmacoeconomics], *infection control, *influenza vaccination, *influenza vaccine/dt [Drug Therapy], *influenza vaccine/pe [Pharmacoeconomics], *influenza/di [Diagnosis], *influenza/dm [Disease Management], *influenza/dt [Drug Therapy], *influenza/ep [Epidemiology], *influenza/pc [Prevention], *oseltamivir/do [Drug Dose], *oseltamivir/dt [Drug Therapy], *oseltamivir/pe [Pharmacoeconomics], *oseltamivir/po [Oral Drug Administration], *pandemic/dm [Disease Management], *pandemic/ep [Epidemiology], *pandemic/pc [Prevention], *zanamivir/do [Drug Dose], *zanamivir/dt [Drug Therapy], *zanamivir/ih [Inhalational Drug Administration], *zanamivir/pe [Pharmacoeconomics], Influenza virus A, Pneumococcus vaccine/dt [Drug Therapy], Pneumococcus vaccine/pe [Pharmacoeconomics], Singapore, amoxicillin plus clavulanic acid/dt [Drug Therapy], amoxicillin plus clavulanic acid/pe [Pharmacoeconomics], amoxicillin plus clavulanic acid/po [Oral Drug Administration], antibiotic agent/dt [Drug Therapy], antibiotic agent/pe [Pharmacoeconomics], antibiotic prophylaxis, antibiotic therapy, antivirus agent/do [Drug Dose], antivirus agent/dt [Drug Therapy], antivirus agent/pe [Pharmacoeconomics], bacterial infection/dm [Disease Management], bacterial infection/dr [Drug Resistance], bacterial infection/dt [Drug Therapy], bacterial infection/ep [Epidemiology], bacterial infection/pc [Prevention], bacterial pneumonia/dm [Disease Management], bacterial pneumonia/dt [Drug Therapy], bacterial pneumonia/ep [Epidemiology], bacterial pneumonia/pc [Prevention], cefazolin/dt [Drug Therapy], cefazolin/pe [Pharmacoeconomics], ceftriaxone/dt [Drug Therapy], ceftriaxone/im [Intramuscular Drug Administration], ceftriaxone/iv [Intravenous Drug Administration], ceftriaxone/pa [Parenteral Drug Administration], ceftriaxone/pe [Pharmacoeconomics], clarithromycin/dt [Drug Therapy], clarithromycin/pe [Pharmacoeconomics], clarithromycin/po [Oral Drug Administration], clinical decision making, clinical practice, disease severity, disinfectant agent, disinfection, drug cost, drug industry, drug safety, evidence based practice, face mask, hand washing, health care personnel, health care policy, high risk population, human, hypochlorite sodium, influenza/dt [Drug Therapy], methicillin resistant Staphylococcus aureus, nonhuman, phenol derivative, pneumococcal infection/dm [Disease Management], pneumococcal infection/dt [Drug Therapy], pneumococcal infection/ep [Epidemiology], pneumococcal infection/pc [Prevention], powered air purifying respirator, practice guideline, protective equipment, quinoline derived antiinfective agent/dt [Drug Therapy], quinoline derived antiinfective agent/pe [Pharmacoeconomics], quinoline derived antiinfective agent/po [Oral Drug Administration], recommended drug dose, respiratory tract infection/di [Diagnosis], respiratory tract infection/dm [Disease Management], respiratory tract infection/dt [Drug Therapy], respiratory tract infection/ep [Epidemiology], respiratory tract infection/pc [Prevention], review, sialidase inhibitor/do [Drug Dose], sialidase inhibitor/dt [Drug Therapy], sialidase inhibitor/pe [Pharmacoeconomics], vancomycin/dt [Drug Therapy], vancomycin/pe [Pharmacoeconomics], ventilator, virus infection/di [Diagnosis], virus infection/dm [Disease Management], virus infection/ep [Epidemiology], virus infection/pc [Prevention], virus transmission, virus virulence},
	pages = {567--580},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021